Radcliffe Capital Management’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Radcliffe Capital Management’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-104,047	Closed	-$1.04M	–	976
2022 Q3	$1.04M	Hold	104,047	–	–	0.03%	887
2022 Q2	$1.03M	Buy	104,047 +247	+0.2%	+$2.44K	0.02%	932
2022 Q1	$1.02M	Buy	103,800 +3,800	+4%	+$37.3K	0.02%	923
2021 Q4	$974K	Hold	100,000	–	–	0.03%	852
2021 Q3	$979K	Hold	100,000	–	–	0.03%	694
2021 Q2	$968K	Hold	100,000	–	–	0.03%	747
2021 Q1	$965K	Buy	+100,000	New	+$971K	0.04%	590

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Radcliffe Capital Management's PKBO Position: Q4 2022 in Review

Radcliffe Capital Management sold out of Peak Bio, Inc. Common Stock (PKBO) in Q4 2022, closing a stake of 104,047 shares — an estimated $1.04M sold.

Radcliffe Capital Management first reported a position in PKBO in Q1 2021 and held it in 7 quarters. The position peaked at $1.04M in Q3 2022. 9 funds tracked by Wall St. Rank hold PKBO as of Q4 2022.

Radcliffe Capital Management reported no remaining Peak Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Radcliffe Capital Management sold 104,047 Peak Bio, Inc. Common Stock shares in Q4 2022, an estimated $1.04M.
Radcliffe Capital Management first reported a position in Peak Bio, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Radcliffe Capital Management's Peak Bio, Inc. Common Stock position peaked at $1.04M in Q3 2022.
9 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q4 2022.

Based on Radcliffe Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.